Cancer Profiling Market

Cancer Profiling Analysis and Forecast by Fact.MR

• The Cancer Profiling Market is expected to grow from USD 12.5 billion in 2026 to USD 36.0 billion by 2036, at a 11.2% CAGR.
• Driven by companion-diagnostic label expansion across solid tumors, rising liquid biopsy adoption for treatment selection and monitoring, and improving payer coverage including minimal residual disease reimbursement, with Genomic Cancer Profiling Tests accounting for 64.7% share.
• Oncology Diagnostics contributing 58.9% share as providers prioritize earlier detection, treatment-selection accuracy, and resource efficiency across clinical settings.

Summary of Cancer Profiling Market

• Market Snapshot
  • In 2025, the global Cancer Profiling Market was valued at approximately USD 11.2 billion.
  • The market is estimated to reach USD 12.5 billion in 2026 and is projected to attain USD 36.0 billion by 2036.
  • The market is likely to expand at a CAGR of 11.2% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 23.6 billion between 2026 and 2036.
  • Genomic Cancer Profiling Tests accounts for 64.7% of product share in 2026.
  • China (15.1%) and India (14.0%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Companion diagnostic label expansion is moving comprehensive profiling from a research adjunct toward a treatment-selection requirement, with assays such as Guardant360 CDx adding solid-tumor indications that pull demand into routine oncology.
  • Liquid biopsy adoption is rising as single blood-sample genomic profiling across solid tumors reduces reliance on tissue and supports serial monitoring, broadening the addressable testing population.
  • Medicare and payer coverage decisions, including minimal residual disease assay reimbursement, are improving the economics of profiling and accelerating clinical uptake.
  • Expansion of companion-diagnostic labels beyond lung into colorectal and other solid tumors creates pull-through demand for comprehensive assays.
  • Genomic AI and evidence-generation collaborations can lower interpretation cost and accelerate clinical adoption of next-generation sequencing.
• Product and Segment View
  • Genomic Cancer Profiling Tests accounts for 64.7% of the product segment in 2026, emerging as the leading category.
  • Oncology Diagnostics accounts for 58.9% of the application segment in 2026, making it the dominant use setting.
  • Key segmentation includes:
    • Product: Genomic Cancer Profiling Tests, Liquid Biopsy Profiling Tests, Bioinformatics Analysis Platforms
    • Application: Oncology Diagnostics, Precision Medicine Applications, Clinical Research Applications
    • End Use: Hospitals & Oncology Centers, Diagnostic Laboratories, Academic & Research Institutes
    • Technology: Next Generation Sequencing, PCR Based Cancer Testing, Microarray Technology
    • Formulation: Laboratory Based Testing Services, On Site Testing Systems, Digital Analysis Platforms
    • Distribution Channel: Direct Institutional Sales, Diagnostic Service Providers, Online Diagnostic Platforms
  • These systems enable:
    • Comprehensive genomic tumor characterization
    • Therapy and companion-diagnostic selection
    • Serial liquid biopsy monitoring
• Geography and Competitive Outlook
  • North America leads on comprehensive profiling adoption, companion-diagnostic label expansion, and payer coverage that funds liquid biopsy and minimal residual disease testing.
  • Europe demand reflects structured oncology networks and IVDR compliance shaping assay qualification across reference laboratories.
  • The steepest regional growth sits in Asia Pacific, where rising cancer incidence and sustained genomics investment in China and India widen the profiling base.
  • China (15.1%) and India (14.0%) lead country growth, with other major markets showing steady demand.
  • Key companies include Illumina, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), Guardant Health, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, Inc..
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says "Cancer profiling is crossing from research adjunct to treatment-selection requirement, and companion-diagnostic labels are the lever. As Guardant360 CDx and similar assays add solid-tumor indications, comprehensive and liquid-biopsy testing moves into routine oncology. The economics now turn on coverage decisions, including minimal residual disease reimbursement, which fund longitudinal testing rather than one-time diagnosis. China and India are scaling fastest on rising incidence and genomics investment. The decisive capability is analytics: assays paired with genomic AI and payer relationships win accounts. Players selling sequencing capacity without interpretation and coverage strategy will cede ground to integrated competitors."

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Companion diagnostic label expansion is moving comprehensive profiling from a research adjunct toward a treatment-selection requirement, with assays such as Guardant360 CDx adding solid-tumor indications that pull demand into routine oncology.
• Liquid biopsy adoption is rising as single blood-sample genomic profiling across solid tumors reduces reliance on tissue and supports serial monitoring, broadening the addressable testing population.
• Medicare and payer coverage decisions, including minimal residual disease assay reimbursement, are improving the economics of profiling and accelerating clinical uptake.

Key Market Constraints

• Variable reimbursement across assay types and geographies limits routine use of comprehensive profiling outside well-covered indications.
• Reproducibility, variant-interpretation consistency, and the need for bioinformatics expertise raise barriers to standardized clinical reporting.
• Tissue sample availability and quality continue to constrain comprehensive genomic profiling where liquid biopsy is not yet validated.

Key Opportunity Areas

• Expansion of companion-diagnostic labels beyond lung into colorectal and other solid tumors creates pull-through demand for comprehensive assays.
• Genomic AI and evidence-generation collaborations can lower interpretation cost and accelerate clinical adoption of next-generation sequencing.
• Minimal residual disease and monitoring applications open recurring, longitudinal testing revenue beyond one-time diagnosis.

Segment-wise Analysis of the Cancer Profiling

• Genomic Cancer Profiling Tests holds 64.7% of the product segment in 2026, supported by clinical preference and procurement scale.
• Oncology Diagnostics represents 58.9% of the application segment in 2026, anchored by its dominant care setting.

The Cancer Profiling Market is segmented by product, application, end use, technology, formulation, distribution channel. Demand is shaped by clinical pathway choices, reimbursement exposure, and procurement structure, with leading segments anchored in higher-volume care settings while faster-growing categories capture incremental demand as adoption broadens.

Which Product Segment Dominates the Cancer Profiling?

Genomic Cancer Profiling Tests lead the product segment with 64.7% share in 2026, as comprehensive panels move from research toward treatment-selection requirements. Next-generation sequencing underpins this category, increasingly tied to companion-diagnostic labels that link a single assay to multiple therapy decisions.

The segment is expected to retain leadership as label expansion and liquid biopsy broaden the testable population. Bioinformatics platforms grow in importance as interpretation becomes the bottleneck, but the genomic profiling test itself remains the core revenue driver across hospital and laboratory settings.

Which Application Segment Dominates the Cancer Profiling?

Oncology Diagnostics dominate at 58.9% in 2026, reflecting the central role of tumor characterization in diagnosis and therapy selection. Profiling is embedded in solid-tumor pathways where companion-diagnostic results determine treatment eligibility.

The application is likely to hold its lead as comprehensive profiling becomes routine in more tumor types. Precision-medicine and monitoring applications expand through minimal residual disease testing, adding longitudinal volume, but front-line oncology diagnosis remains the largest demand channel.

Which Product Trend is Shaping the Next Phase of Growth in the Cancer Profiling?

Genomic Cancer Profiling Tests hold 64.7% of the product segment, and the defining shift is the move toward comprehensive, often blood-based profiling tied directly to therapy selection. Next-generation sequencing, the leading technology, is being paired with companion-diagnostic labels and genomic AI so that a single assay supports multiple solid-tumor treatment decisions, concentrating demand in hospitals and oncology centers.

Liquid biopsy is the most disruptive force within this shift. Single blood-sample profiling across solid tumors reduces dependence on tissue, supports serial monitoring, and expands testing into earlier and recurrent disease settings. Coverage decisions for minimal residual disease assays reinforce the trend by funding longitudinal testing, supporting sustained demand for laboratory-based testing services.

Regional Outlook Across Key Markets

• North America leads on comprehensive profiling adoption, companion-diagnostic label expansion, and payer coverage that funds liquid biopsy and minimal residual disease testing.
• Europe demand reflects structured oncology networks and IVDR compliance shaping assay qualification across reference laboratories.
• The steepest regional growth sits in Asia Pacific, where rising cancer incidence and sustained genomics investment in China and India widen the profiling base.
• Japan shows steady demand anchored in established molecular pathology and reimbursement for companion diagnostics.

CAGR Table

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

Market Outlook for Cancer Profiling in China

The China Cancer Profiling market is projected to grow at a CAGR of 15.1% through 2036. Government support for genomics self-sufficiency and domestic sequencing capacity is reshaping the cancer profiling landscape, narrowing the gap with imported next-generation sequencing platforms. Centralized procurement influences hospital assay pricing, while expanding oncology centers lift demand for genomic cancer profiling tests and laboratory-based testing services.

• Domestic sequencing capacity is lifting local supply of next-generation sequencing assays into hospital oncology centers.
• Centralized procurement is steering laboratory-based testing service pricing toward cost-competitive providers.

India Cancer Profiling Demand Trends

The India Cancer Profiling market is projected to grow at a CAGR of 14.0% through 2036. Demand is concentrated in metropolitan oncology centers and reference laboratories where rising cancer incidence and growing private oncology investment expand comprehensive genomic profiling. Cost-effectiveness shapes adoption toward laboratory-based testing services and PCR-based cancer testing, while import dependency affects sequencing reagent pricing.

• Private oncology investment is widening access to genomic cancer profiling tests in metro reference laboratories.
• Cost-effectiveness favors PCR-based cancer testing and centralized laboratory-based services over distributed on-site systems.

Cancer Profiling Growth Assessment in Germany

The Germany Cancer Profiling market is projected to grow at a CAGR of 12.9% through 2036. EU IVDR compliance governs how cancer profiling assays qualify and are validated across German reference laboratories, raising evidence and documentation requirements. The GKV reimbursement framework and reference pricing shape which comprehensive profiling tests gain routine funding, favoring next-generation sequencing platforms with strong clinical evidence.

• EU IVDR validation requirements concentrate testing among laboratories with full assay documentation.
• GKV reimbursement pathways shape routine funding for next-generation sequencing comprehensive profiling.

United States Cancer Profiling Market Opportunity Outlook

The United States Cancer Profiling market is projected to grow at a CAGR of 10.6% through 2036. Hospital and oncology-center networks anchor demand, with comprehensive genomic profiling increasingly embedded in treatment-selection pathways. FDA companion-diagnostic approvals and the insurance and reimbursement landscape, including Medicare coverage for minimal residual disease assays, drive adoption of liquid biopsy and next-generation sequencing across specialty oncology practices.

• FDA companion-diagnostic label expansion is pulling comprehensive profiling into routine solid-tumor treatment selection.
• Medicare coverage for minimal residual disease assays supports recurring liquid biopsy testing revenue.

Cancer Profiling Demand Analysis in Japan

The Japan Cancer Profiling market is projected to grow at a CAGR of 8.4% through 2036. Established molecular pathology infrastructure means growth is led by expansion of companion-diagnostic testing and liquid biopsy rather than first-time capacity build-out. PMDA approval pathways and NHI reimbursement revisions shape which assays gain routine use, while preference for validated platforms supports next-generation sequencing demand.

• NHI reimbursement for companion diagnostics sustains demand for validated next-generation sequencing assays.
• Preference for established platforms supports laboratory-based testing services in academic centers.

Competitive Benchmarking and Company Positioning

Cancer Profiling Analysis By Company

• Illumina, Roche through Foundation Medicine, Guardant Health, and Thermo Fisher hold leading positions through sequencing platforms, comprehensive genomic profiling assays, and FDA-approved companion diagnostics with broad clinical reach.
• QIAGEN, NeoGenomics, Caris Life Sciences, and Natera compete across PCR-based testing, laboratory services, and minimal residual disease assays, with payer coverage shaping competitive position.
• Platform and analytics collaborations, including genomic AI partnerships, increasingly differentiate competitors as interpretation and evidence generation become central to clinical adoption.

The competitive landscape is concentrated among integrated sequencing and profiling players, with differentiation driven by assay breadth, companion-diagnostic labels, and payer coverage. Illumina, Roche through Foundation Medicine, Guardant Health, and Thermo Fisher are best positioned to capture treatment-selection demand through comprehensive panels and FDA-approved companion diagnostics that pull through recurring reagent and service revenue.

Below the leaders, QIAGEN, NeoGenomics, Caris Life Sciences, and Natera maintain strong positions in PCR-based testing, reference-laboratory services, and minimal residual disease monitoring. Competition turns on coverage decisions, turnaround time, and the clinical evidence supporting specific indications rather than platform breadth alone.

Analytics is an increasingly decisive battleground. Collaborations linking sequencing with genomic AI and evidence generation, alongside Tempus AI and Agilent's platform positions, raise the value of interpretation and reporting. Companies that combine validated assays with scalable bioinformatics and payer relationships are positioned to deepen account retention.

Key Companies in the Cancer Profiling

• Leading companies in the cancer profiling market include Illumina, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), Guardant Health, Inc., Thermo Fisher Scientific Inc., which hold strong positions through portfolio breadth, clinical evidence, and broad distribution.
• QIAGEN N.V., NeoGenomics Laboratories, Inc., Caris Life Sciences, Natera, Inc. maintain established positions across specific segments and channels, competing on assay or product performance, service, and regional reach.
• Tempus AI, Inc., Agilent Technologies, Inc. and other specialists compete through focused offerings and niche strength, reinforcing relevance in a competitive but evolving market.

Recent Industry Developments

• Guardant Health, Inc. - FDA Companion Diagnostic Expansion for Guardant360 CDx (January 2026)
  • In January 2026, Guardant Health reported FDA approval of Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer eligible for a specific therapy combination. The approval extends companion-diagnostic labels beyond lung into additional solid tumors, supporting comprehensive liquid biopsy demand.
• Thermo Fisher Scientific Inc. - FDA Approval of Oncomine Dx Express Test (July 2025)
  • In July 2025, Thermo Fisher announced FDA approval of the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic companion diagnostic and for tumor profiling. The approval supports decentralized next-generation sequencing in clinical settings.
• Natera, Inc. - Medicare Coverage for Signatera MRD Assay (June 2025)
  • In June 2025, Natera announced that its genome-based Signatera minimal residual disease assay gained Medicare coverage under LCD L38779. The coverage decision strengthens reimbursement for longitudinal liquid biopsy testing and recurring profiling revenue.
• Illumina, Inc. - Genomic AI Collaboration with Tempus AI (April 2025)
  • In April 2025, Illumina and Tempus AI announced a collaboration to accelerate clinical adoption of next-generation sequencing through genomic AI and evidence generation. The partnership targets faster interpretation and broader clinical uptake of comprehensive profiling.

Leading Companies Shaping the Cancer Profiling

• Illumina, Inc.
• F. Hoffmann-La Roche Ltd (Foundation Medicine)
• Guardant Health, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• NeoGenomics Laboratories, Inc.
• Caris Life Sciences
• Natera, Inc.
• Tempus AI, Inc.
• Agilent Technologies, Inc.

Cancer Profiling Segmentation

• Cancer Profiling Market Segmented by Product:

  • Genomic Cancer Profiling Tests
    • Next Generation Sequencing Panels
      • Whole Exome Sequencing Panels
      • Targeted Gene Panels
    • Whole Genome Profiling Tests
      • Somatic Mutation Profiling
      • Germline Mutation Profiling
  • Liquid Biopsy Profiling Tests
    • Circulating Tumor DNA Tests
      • Early Cancer Detection Panels
      • Minimal Residual Disease Tests
    • Circulating Tumor Cell Tests
      • Metastatic Cancer Tracking Tests
      • Treatment Response Monitoring Tests
  • Bioinformatics Analysis Platforms
    • AI Driven Genomic Platforms
      • Predictive Cancer Modeling Tools
      • Mutation Pattern Recognition Systems
    • Data Interpretation Software
      • Clinical Reporting Platforms
      • Variant Annotation Systems

• Cancer Profiling Market Segmented by Application:

  • Oncology Diagnostics
    • Solid Tumor Profiling
      • Lung Cancer Profiling Applications
      • Breast Cancer Profiling Applications
    • Hematological Cancer Profiling
      • Leukemia Profiling Applications
      • Lymphoma Profiling Applications
  • Precision Medicine Applications
    • Therapy Selection Applications
      • Targeted Therapy Matching
      • Immunotherapy Suitability Testing
    • Treatment Optimization Applications
      • Drug Resistance Profiling
      • Dose Optimization Studies
  • Clinical Research Applications
    • Drug Development Studies
      • Clinical Trial Stratification
      • Biomarker Discovery Studies
    • Academic Research Applications
      • Cancer Genomics Research
      • Population Based Cancer Studies

• Cancer Profiling Market Segmented by End Use:

  • Hospitals & Oncology Centers
    • Cancer Specialty Hospitals
      • Comprehensive Cancer Centers
      • Regional Oncology Hospitals
    • Multi Specialty Hospitals
      • Integrated Oncology Departments
      • Tertiary Care Hospitals
  • Diagnostic Laboratories
    • Molecular Diagnostic Labs
      • Genetic Testing Laboratories
      • Pathology Reference Labs
    • Independent Testing Labs
      • Private Diagnostic Chains
      • Specialized Cancer Labs
  • Academic & Research Institutes
    • Medical Research Universities
      • Cancer Research Institutes
      • Genomics Research Centers
    • Clinical Trial Organizations
      • Pharmaceutical Research Units
      • Biotech Research Labs

• Cancer Profiling Market Segmented by Technology:

  • Next Generation Sequencing
    • High Throughput Sequencing
      • Massively Parallel Sequencing Systems
      • Ultra Deep Sequencing Platforms
    • Targeted Sequencing Technology
      • Cancer Gene Panel Sequencing
      • Hotspot Mutation Sequencing
  • PCR Based Cancer Testing
    • Real Time PCR Systems
      • Quantitative Mutation Detection
      • Expression Level Analysis Systems
    • Digital PCR Systems
      • Ultra Sensitive Mutation Detection
      • Copy Number Variation Analysis
  • Microarray Technology
    • DNA Microarray Systems
      • Gene Expression Profiling Arrays
      • Mutation Screening Arrays
    • Protein Microarray Systems
      • Cancer Biomarker Detection Arrays
      • Antibody Interaction Profiling

• Cancer Profiling Market Segmented by Formulation:

  • Laboratory Based Testing Services
    • Centralized Genomic Testing Labs
      • High Complexity Testing Labs
      • Reference Oncology Laboratories
    • Specialized Molecular Labs
      • Cancer Genomics Labs
      • Biomarker Analysis Labs
  • On Site Testing Systems
    • Point of Care Genetic Testing
      • Rapid Molecular Testing Kits
      • Bedside Cancer Screening Tools
    • Portable Diagnostic Systems
      • Mobile Genetic Analysis Units
      • Field Deployable Testing Systems
  • Digital Analysis Platforms
    • Cloud Genomics Platforms
      • AI Based Interpretation Systems
      • Remote Reporting Platforms
    • Bioinformatics Platforms
      • Variant Analysis Software
      • Cancer Risk Prediction Engines

• Cancer Profiling Market Segmented by Distribution Channel:

  • Direct Institutional Sales
    • Hospital Procurement Contracts
      • Oncology Department Agreements
      • Diagnostic Procurement Programs
    • Research Institution Contracts
      • University Lab Supply Agreements
      • Clinical Trial Supply Contracts
  • Diagnostic Service Providers
    • Reference Laboratories
      • National Diagnostic Chains
      • Regional Testing Laboratories
    • Specialized Genetic Testing Labs
      • Cancer Screening Service Providers
      • Private Genomic Labs
  • Online Diagnostic Platforms
    • Digital Health Platforms
      • Telemedicine Diagnostic Services
      • Remote Sample Testing Platforms
    • E Health Marketplaces
      • Patient Direct Testing Platforms
      • Subscription Based Genomic Services

• Cancer Profiling Market by Region:

  • North America
    • USA
    • Canada
    • Mexico
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Western Europe
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Nordic
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Hungary
    • Balkan & Baltic
    • Rest of Eastern Europe
  • East Asia
    • China
    • Japan
    • South Korea
  • South Asia and Pacific
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of South Asia and Pacific
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkiye
    • South Africa
    • Other African Union
    • Rest of Middle East & Africa

Sources and Research References

• Guardant Health, Inc. (2026). FDA approval expands Guardant360 CDx companion diagnostic indications for BRAF V600E-mutant metastatic colorectal cancer. Guardant Health, Inc.
• Thermo Fisher Scientific Inc. (2025). FDA approves Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer for companion diagnostics and tumor profiling. Thermo Fisher Scientific Inc.
• Natera, Inc. (2025). Signatera minimal residual disease assay receives Medicare coverage under LCD L38779. Natera, Inc.
• Illumina, Inc., & Tempus AI, Inc. (2025). Illumina and Tempus AI announce collaboration to accelerate clinical adoption of next-generation sequencing through genomic AI and evidence generation. Illumina, Inc. & Tempus AI, Inc.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Cancer Profiling Market?
• How fast is the Cancer Profiling Market expected to grow between 2026 and 2036?
• Which product segment is likely to lead the market by 2026?
• Which application segment is expected to account for the highest demand by 2026?
• What factors are driving demand in the cancer profiling market globally?
• Which countries are projected to show the fastest growth through 2036?
• What is driving market expansion in China and India?
• Who are the key companies active in the cancer profiling market?
• How is companion-diagnostic label expansion changing routine profiling demand?
• What is the role of liquid biopsy and minimal residual disease testing in recurring revenue?
• How does Fact.MR estimate and validate the cancer profiling market forecast?

Cancer Profiling Market Definition

The cancer profiling market covers genomic and molecular tests, liquid biopsy assays, and bioinformatics platforms used to characterize tumors for diagnosis, treatment selection, and monitoring. It spans next-generation sequencing, PCR-based testing, and microarray technologies delivered through laboratory services, on-site systems, and digital analysis platforms across hospitals, diagnostic laboratories, and research institutes.

Cancer Profiling Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product type, application, end use, technology, formulation, and distribution channel.
• It includes demand tied to comprehensive genomic profiling, companion diagnostics, minimal residual disease testing, and liquid biopsy adoption in oncology.
• Pricing and reimbursement analysis spans tissue and blood-based assays, including Medicare and payer coverage dynamics in major markets.
• Coverage includes bioinformatics and digital analysis platforms supporting variant interpretation and clinical reporting.

Cancer Profiling Market Exclusions

• The scope excludes general clinical chemistry and routine pathology not specific to molecular tumor characterization.
• It excludes cancer therapeutics and drug products, which are addressed in separate oncology coverage.
• Research-use-only reagents without a diagnostic or clinical-profiling application are excluded.
• Imaging-based cancer detection without molecular profiling content is excluded.

Cancer Profiling Market Research Methodology

• The methodology combines secondary research, primary interviews, and demand-side modeling.
• It draws on 130 plus secondary sources and benchmarks 60 plus assay and platform portfolios.
• Market sizing covers 30 plus countries through a test-volume and oncology-incidence model with top-down validation.
• Key inputs include cancer incidence, comprehensive genomic profiling adoption, companion-diagnostic label expansion, and payer coverage.
• The model cross-checks test demand with sequencing instrument placements, reagent pull-through, and laboratory volumes.
• Primary validation includes 25 plus interviews across oncologists, laboratory directors, payers, and assay developers.
• Final estimates pass through coverage-policy review, adoption-curve analysis, and sensitivity testing.